Immune Checkpoint Inhibitor
Immunotherapy specialist appointed research center's scientific director
Fred Hutchinson Cancer Center appointed Lawrence Fong, MD, as scientific director of the Immunotherapy Integrated Research Center.
Anti-CTLA-4 immune checkpoint inhibitor may hold promise for glioblastoma treatment
Researchers at Salk Institute for Biological Studies have achieved promising results in early studies using an anti-CTLA-4 antibody for treatment of glioblastoma, the most common and deadliest form of brain cancer.
Immunotherapy may benefit certain patients with penile cancer
Immune checkpoint inhibitors may confer benefit to certain patients with advanced penile squamous cell carcinoma, according to retrospective study results.
Radiotherapy fails to improve effectiveness of checkpoint inhibitors for solid tumors
The addition of stereotactic body radiotherapy to immune checkpoint inhibitors failed to significantly extend survival among individuals with advanced solid tumors, results of the randomized phase 2 CHEERS trial showed.
Immune checkpoint inhibitors ‘safe and effective’ for people living with HIV, cancer
People living with HIV and various cancer types may be safely treated with immune checkpoint inhibitors, according to results of a retrospective study published in Journal of Clinical Oncology.
Incidence of cancer-associated thrombosis remains high over time, varies with therapy
Incidence of venous thromboembolism remained high among patients with cancer even as the treatment landscape has evolved over the past 16 years, according to data published in JAMA Network Open.
Oncologists play key role in diagnosing immune checkpoint inhibitor-induced myocarditis
Incidence of immune checkpoint inhibitor-induced myocarditis may increase as more patients receive immunotherapy. In this special report, Healio | HemOnc Today highlights how a multidisciplinary approach can reduce mortality through early recognition and prompt intervention.
Tumor-treating fields extend OS in metastatic NSCLC
CHICAGO — The addition of tumor-treating fields to second-line therapy prolonged survival for patients with metastatic non-small cell lung cancer whose disease progressed on or after platinum therapy, according to results presented at ASCO Annual Meeting.
Tumor mutational burden may be linked to immunotherapy response in advanced cancers
Cancers with high vs. low tumor mutational burden appeared significantly associated with improved clinical outcomes among patients treated with immune checkpoint inhibitors, according to data published in JAMA Network Open.
Specificity of definition of ICI-related myocarditis improved after minor change
A modified version of the International Cardio-Oncology Society definition of immune checkpoint inhibitor-associated myocarditis may improve its predictive value, researchers reported.